This month’s journal-based CME article is titled "Safety of Locoregional Treatment During Immunotherapy With Nivolumab For Hepatocellular Carcinoma: A Retrospective Study of Forty-one Interventions in Twenty-nine Patients".
This is a retrospective single center review of patients undergoing locoregional therapy (LRT) for hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) and/or transarterial radioembolization (TARE). The study included 29 patients who underwent 41 LRT treatments. Within sixty days or concurrently, patients were also administered the immune checkpoint inhibitor nivolumab. Review of outcomes and analysis of adverse events were then perform
To receive CME credit for this journal-based CME activity, participants must read the journal article and score 75% or better on the post test. Participants will have three opportunities to score 75% or better.
After participating in this journal-based CME activity, learners should be able to:
- Review the frequency and severity of adverse events with LRT and nivolumab.
- Describe potential timing of nivolumab administration relative to LRT.
JVIR CME Editor
Daniel Sheeran, MD
University of Virginia, Charlottesville, VA
Brett Marinelli, MD MSCR1
Mario Cedillo, MD1
Sara D. Pasik, BA1
Dudley Charles, BA1
Shashi Murthy, MD1
Rahul S. Patel, MD, FSIR1
Aaron Fischman, MD, FSIR1
Monda Ranade, MD1
Vivian Bishay, MD1
Scott Nowakowski, MD1
Max Sung, MD2
Thomas Marron, MD PhD2
Robert Lookstein, MD, MHCDL FAHA FSVM FSIR1
Myron Schwartz, MD3
Edward Kim, MD, FSIR1
1 Icahn School of Medicine at Mount Sinai Division of Interventional Radiology
2 Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology
3 Icahn School of Medicine at Mount Sinai Recanti/Miller Transplantation Institute
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME).
The Society of Interventional Radiology (SIR) is accredited by the ACCME to provide continuing medical education for physicians. SIR designates this education activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is approved for 1 self-assessment CME credit (SA-CME) by the Society of Interventional Radiology (SIR) - approved October 1, 2020. SIR is awarded Deemed Status by the American Board of Radiology (ABR). The SA-CME credit offered for this enduring activity meets the ABR’s criteria for self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification (MOC) Program.